PRIMARY STUDY
Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia
Key Findings: The endocannabinoid system (ECS) via CB1 receptor activation in this model of Schizophrenia in early exposure of rats to methylazoxymethanol acetate (MAM), shows promise a therapuritc target and for better understanding of the ECS role in Schizophrenia. More specifically, AM251 reversed schizophrenia-like deficits in the test animals.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Canada, Czech Republic, Germany, Italy
Year of Pub: 2022
Cannabinoids Studied: AM-x Synthetic Cannabinoids, Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1
Ligands Studied: Glutamate, Neurotransmitter (unspecified/other)
Route of Administration: Injection
Citation: Stark T, et al. Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules. 2022; 12:(unknown pages). doi: 10.3390/biom12010108
Authors: Stark T, Iannotti FA, Di Martino S, Di Bartolomeo M, Ruda-Kucerova J, Piscitelli F, Wotjak CT, D'Addario C, Drago F, Di Marzo V, Micale V
